Navigation Links
Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
Date:11/1/2007

COLUMBIA, Md., Nov. 1 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) today announced that a judge in the United States District Court in Wilmington, Delaware, has ruled on various post-trial motions and will enter a permanent injunction in Martek's favor against the defendants in the patent infringement suit brought by Martek against Lonza, Ltd., Nutrinova Inc. and Nutrinova Nutrition Specialties & Food Ingredients GmbH. The suit involves Lonza's U.S. sale and use of a fatty acid product currently marketed under the brand name Lonza DHA for use in functional foods and dietary supplements and does not involve Martek's core infant formula patents.

The judge upheld the October 2006 jury verdict that the defendants infringed all of the asserted claims of U.S. Patent Nos. 5,340,594 and 6,410,281 (the "'281 Patent") and that these patents were valid. The judge indicated that he will grant a permanent injunction against Lonza with respect to those two patents. The judge also upheld the jury verdict that Lonza had acted willfully in its infringement of the '281 Patent. Regarding the third patent involved in the case, U.S. Patent No. 6,451,567 (the "'567 Patent"), the judge reversed the jury verdict and found that there was insufficient evidence to show that the claims of this patent are enforceable against the defendants. Martek does not believe that this decision will have an adverse effect on the strength of the permanent injunction to be issued by the Court.

Martek expects that Lonza will appeal the adverse decision against it to the U.S. Court of Appeals for the Federal Circuit. The permanent injunction will be in effect pending any appeal. Martek is considering the alternatives availa
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quality assurance of RNA derived from laser microdissected tissue samples obtained by the PALM MicroBeam System using the RNA 6000 Pico LabChip kit.
2. High Electrotransformation Efficiencies Obtained With DNA From Ligation Mixtures
3. Obtaining a contour map from multifiles or 3D data in DataMax
4. Third Wave strikes deal with Kaiser Permanente on cystic fibrosis reagents
5. Third Wave sued by one firm; gets injunction against another
6. Protector RNase Inhibitor Enhance the Protection of RNA against Degradation
7. Protecting your business against online brand abuse
8. NovaScan decides against tax credits
9. Journalist warns against late arrival to the tech party
10. Wisconsin companies on the front lines in the war against cancer
11. Guarding against patent enforcement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  PDS Biotechnology ... cancer immunotherapy treatment targeting HPV-16, has generated strong ... Currently, pre-cervical cancer is treated by surgical ... simple and effective non-surgical alternative. Results show that ... (T-cells) to recognize, target, and kill precancerous and ...
(Date:5/28/2015)... The Fertility Centers of New England is proud to ... on a new and expanded role as Medical Director. ... oversight and quality assurance for the practice. , “We ... of experienced reproductive endocrinologists,” said Fertility Centers of New ... expertise and compassionate, individualized care have helped set FCNE ...
(Date:5/28/2015)... Rochelle, Virginia (PRWEB) May 28, 2015 ... Partners LLC announced today that Roger L. Williams, ... Expert consultant. NDA Partners Premier Experts are top ... them to bring extraordinary value to the company’s ... critical solutions to help clients successfully develop their ...
(Date:5/27/2015)... 26, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Molecular ... to their offering. This report ... that will play an important role in ... forensics and biological warfare in the 21st ...
Breaking Biology Technology:PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 3
... Osaka, Japan, for the Bio Japan 2006 conference as ... of times over the years about both the Japanese pharma and ... few years and I'm looking forward to getting up to speed ... reminder: Chicago and Osaka are sister cities and my last visit ...
... EraGen Biosciences , a Madison-based developer of diagnostic ... outline its product development plans. , ,Irene Hrusovsky, CEO ... of the company to attendees of the Mid-America ... of ZyStor Therapeutics, Inc. , a Milwaukee-based developer ...
... other TV news broadcasts, the accusation that Hewlett ... of directors was revealed. Because she was afraid that ... Patricia Dunn, unilaterally authorized a project headed up by ... personal phone records of board members. www.msnbc.msn.com/id/14687677/site/newsweek ...
Cached Biology Technology:Chinese pharma-biotech dragon rears its head 2Chinese pharma-biotech dragon rears its head 3Chinese pharma-biotech dragon rears its head 4Chinese pharma-biotech dragon rears its head 5Chinese pharma-biotech dragon rears its head 6EraGen set to highlight diagnostic products at BIO 2Compliance at HP - Pretexting paranoia 2Compliance at HP - Pretexting paranoia 3Compliance at HP - Pretexting paranoia 4Compliance at HP - Pretexting paranoia 5
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Yamanaka MD, PhD, of Kyoto University and the Gladstone ... forward in improving the possibilities for the practical application ... Dr. Yamanaka had shown that adult cells can be ... oncogene as one of the four genes required to ...
... Jim Doyle today announced a historic collaboration between ... care leading to health care that proactively addresses ... research effort among the Marshfield Clinic, Medical College ... Medicine and Public Health (UWSMPH) and UW-Milwaukee (UWM). ...
... one of the most thoroughly studied organisms in the ... understanding variation in physiology, behavior, life history and morphology ... On biological levels from molecular and genetic to developmental ... it has proven far more complex than even imagined. ...
Cached Biology News:Yamanaka eliminates viral vector in stem cell reprogramming 2Governor Doyle announces historic genomic research collaboration 2Fitness in a changing world 2Fitness in a changing world 3
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
... Spring offers a large collection of ... fetal tissuea, cell lines, and mouse ... in pHD9 vector. The size of ... be from 200bp to 1000bp by ...
... #27295 has improved stability and convenience from the ... only has overcome this problem but also produced ... changed the formulation of HRP conjugated antibody from ... this change, the stability of the conjugate has ...
Biology Products: